Swiss gene-editing specialist CRISPR Therapeutics (Nasdaq: CRSP) and San Diego, USA-based Sirius Therapeutics, which is ...

CRISPR Therapeutics is paying $25 million upfront to work on multiple siRNA targets with Sirius Tx with an early focus on the ...

Collaboration brings together complementary capabilities to co-develop and co-commercialize SRSD107, a next generation, ...